1. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA.
- Author
-
Garfein, Richard S., Lin Liu, Cuevas-Mota, Jazmine, Collins, Kelly, Muñoz, Fatima, Catanzaro, Donald G., Moser, Kathleen, Higashi, Julie, Al-Samarrai, Teeb, Kriner, Paula, Vaishampayan, Julie, Cepeda, Javier, Bulterys, Michelle A., Martin, Natasha K., Rios, Phillip, Raab, Fredric, and Liu, Lin
- Subjects
- *
MYCOBACTERIUM tuberculosis , *DIRECTLY observed therapy , *PATIENT compliance , *PREVENTIVE medicine , *MEDICAL care , *DRUG therapy for tuberculosis , *ANTITUBERCULAR agents , *TUBERCULOSIS epidemiology , *COMPARATIVE studies , *DRUGS , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *VIDEO recording , *COST analysis , *EVALUATION research - Abstract
We assessed video directly observed therapy (VDOT) for monitoring tuberculosis treatment in 5 health districts in California, USA, to compare adherence between 174 patients using VDOT and 159 patients using in-person directly observed therapy (DOT). Multivariable linear regression analyses identified participant-reported sociodemographics, risk behaviors, and treatment experience associated with adherence. Median participant age was 44 (range 18-87) years; 61% of participants were male. Median fraction of expected doses observed (FEDO) among VDOT participants was higher (93.0% [interquartile range (IQR) 83.4%-97.1%]) than among patients receiving DOT (66.4% [IQR 55.1%-89.3%]). Most participants (96%) would recommend VDOT to others; 90% preferred VDOT over DOT. Lower FEDO was independently associated with US or Mexico birth, shorter VDOT duration, finding VDOT difficult, frequently taking medications while away from home, and having video-recording problems (p<0.05). VDOT cost 32% (range 6%-46%) less than DOT. VDOT was feasible, acceptable, and achieved high adherence at lower cost than DOT. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF